p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy
for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
Medical versus surgical androgen suppression therapy
for prostate cancer: A 10-year longitudinal cost study.
Influence of androgen suppression therapy
for prostate cancer on the frequency and timing of fatal myocardial infarctions.
Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy
for prostate cancer without bone metastases: a randomized controlled trial.
ORLANDO -- Periodic breaks from androgen suppression therapy
did not impact survival in men with prostate-specific antigen progression after radical therapy for prostate cancer.
The rest of the men were treated with external-beam radiation therapy (n = 209); external-beam radiation with androgen suppression therapy (n = 90); brachytherapy (n = 271); or brachytherapy with either external-beam radiation or androgen suppression therapy (n = 35).
The researchers found that androgen suppression therapy had a negative effect on vitality, which includes mood and energy.
SEATTLE -- It's known that patients undergoing combined androgen suppression therapy
for prostate cancer may experience decreases in penile and testicular volume, but physicians don't always inform patients of this risk, Dr.
Causes of death in men undergoing androgen suppression therapy
for newly diagnosed localized or recurrent prostate cancer.
"The study team has a high degree of confidence that gabapentin, at a dose of 900 mg/day, moderately decreases hot flashes related to androgen suppression therapy
," said Dr.
In 2010, the Prostate (PR).3 trial results were reported at the American Society of Clinical Oncology (ASCO)[sup.20] and plenary session of the American Society of Therapeutic Radiology and Oncology.[sup.21] These results confirm the role of radiation therapy for men with locally-advanced prostate and are regarded as practice-changing.[sup.22] In 2011, the results of PR.7 demonstrating the non-inferiority of intermittent as opposed to continuous androgen suppression therapy
were presented at ASCO and recognized as one of the less that 1% of all abstracts categorized as "the Best of ASCO."[sup.23] In contrast, three trials, Bladder.11, PR.11 and PR.12 were closed due to accrual failure.
Luteinizing hormone releasing-hormone agonists (LHRH-A) are widely used as androgen suppression therapy
(AST) for localized and metastatic prostate cancer.